Physician profile
Mei Wang
NPI 1538843370
$700.00
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $162.56 | 2024 | |
| Novo Nordisk INC | $106.13 | 2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $86.04 | 2024 | Jardiance, Zepbound |
| Lundbeck LLC | $66.21 | 2024 | Rexulti |
| Pfizer INC. | $46.62 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.89 | 2024 | Jardiance |
| Edwards Lifesciences Corporation | $35.15 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Otsuka America Pharmaceutical, INC. | $25.72 | 2024 | Rexulti |
| Genentech USA, INC. | $24.62 | 2024 | Xolair |
| Abbott Laboratories | $21.40 | 2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $18.19 | 2024 | Airsupra |
| Glaxosmithkline, LLC. | $14.95 | 2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2024 | Trintellix |
| Exact Sciences Corporation | $13.82 | 2024 | Cologuard Collection Kit |
| Almatica Pharma LLC | $13.68 | 2024 | Loreev Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.15 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.